IRIS PubliCatt

Miele, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.856
NA - Nord America 5.707
AS - Asia 1.613
AF - Africa 34
OC - Oceania 29
SA - Sud America 28
Continente sconosciuto - Info sul continente non disponibili 21
Totale 14.288
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.675
DE - Germania 2.344
SE - Svezia 1.475
IT - Italia 896
CN - Cina 808
IE - Irlanda 549
UA - Ucraina 478
SG - Singapore 379
FR - Francia 216
RU - Federazione Russa 205
GB - Regno Unito 191
FI - Finlandia 188
TR - Turchia 143
IN - India 127
BE - Belgio 80
PL - Polonia 54
HK - Hong Kong 52
CH - Svizzera 50
IR - Iran 41
CZ - Repubblica Ceca 40
AU - Australia 25
JP - Giappone 24
CI - Costa d'Avorio 21
EU - Europa 18
NL - Olanda 17
BR - Brasile 16
CA - Canada 13
RO - Romania 13
ES - Italia 12
AT - Austria 11
PT - Portogallo 11
MX - Messico 8
CL - Cile 6
IL - Israele 6
VN - Vietnam 6
BZ - Belize 5
DK - Danimarca 5
HU - Ungheria 5
KR - Corea 5
NG - Nigeria 4
NZ - Nuova Zelanda 4
PH - Filippine 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
EE - Estonia 3
EG - Egitto 3
GR - Grecia 3
MY - Malesia 3
PA - Panama 3
A2 - ???statistics.table.value.countryCode.A2??? 2
HR - Croazia 2
ID - Indonesia 2
IQ - Iraq 2
KG - Kirghizistan 2
NO - Norvegia 2
PK - Pakistan 2
PR - Porto Rico 2
RE - Reunion 2
SC - Seychelles 2
A1 - Anonimo 1
AR - Argentina 1
BO - Bolivia 1
BY - Bielorussia 1
DJ - Gibuti 1
GT - Guatemala 1
MA - Marocco 1
MC - Monaco 1
MD - Moldavia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
PY - Paraguay 1
RS - Serbia 1
SA - Arabia Saudita 1
SI - Slovenia 1
TH - Thailandia 1
TW - Taiwan 1
Totale 14.288
Salva come PNG Salva come JPEG
Città #
Chandler 1.075
Dublin 549
Ashburn 489
Chicago 314
Jacksonville 279
San Mateo 248
Singapore 236
New York 195
Nanjing 189
Rome 169
Milan 165
Moscow 157
Nürnberg 154
Wilmington 146
Ann Arbor 143
Boston 137
Izmir 123
Houston 122
Marseille 115
Princeton 113
Dearborn 106
Cattolica 100
Munich 94
Beijing 91
Helsinki 89
Los Angeles 87
Woodbridge 84
Brussels 79
Nanchang 77
Seattle 72
Boardman 66
Redmond 53
Kraków 50
Fairfield 49
Hong Kong 48
Hebei 45
Redwood City 44
Zurich 40
Shenyang 39
Tianjin 39
Bremen 38
Brno 35
Lawrence 35
Kunming 31
Norwalk 30
Zhengzhou 30
San Jose 27
Changsha 26
Mountain View 26
Fremont 24
Pune 23
Guangzhou 22
Hangzhou 22
Abidjan 21
Jiaxing 21
University Park 21
Washington 19
Augusta 18
Andover 17
Castelnuovo di Val di Cecina 17
Nuremberg 17
Cambridge 16
Kish 16
Leawood 16
London 16
Portland 16
Trieste 16
Jinan 15
San Diego 15
Busto Arsizio 13
Falls Church 13
Lancaster 13
Lanzhou 12
Ningbo 12
Boydton 11
Phoenix 10
Simi Valley 10
Stockholm 10
Taizhou 10
Tokyo 10
Atlanta 9
Hefei 9
Palermo 9
Rio de Janeiro 9
Campagna 8
Shanghai 8
Amsterdam 7
Bern 7
Frankfurt am Main 7
Gunzenhausen 7
Lappeenranta 7
Provo 7
Vienna 7
Buffalo 6
Chiswick 6
Detroit 6
Falkenstein 6
Ferrara 6
Genoa 6
Hounslow 6
Totale 7.383
Salva come PNG Salva come JPEG
Nome #
Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging 382
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 204
13C-methionine breath tests for mitochondrial liver function assessment. 201
A phase II study of sunitinib in advanced hepatocellular carcinoma 200
13C-breath tests in the study of microsomal liver function 190
gc) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. 180
-Hepatic steatosis and vascular disease 166
Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms 158
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis 152
Role of diffusion-weighted imaging, apparent diffusion coefficient and correlation with hepatobiliary phase findings in the differentiation of hepatocellular carcinoma from dysplastic nodules in cirrhotic liver 150
134C-breath tests in the study of mitochondrial liver function 147
Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. 144
Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms 141
Effect of sildenafil on diabetic gastropathy. 136
Non Alcoholic Fatty Liver Disease is Associated with Increased GHBP and Reduced GH/IGF-I Levels 135
13C-breath tests in the study of microsomial liver function 135
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 132
Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm 130
Non Alcoholic Fatty Liver Disease is Associated with Increased GHBP and Reduced GH/IGF-I Levels 124
13C-methionine breath tests for mitochondrial liver function assessment 122
The Effect of CYP, GST, and SULT Polymorphisms and Their Interaction with Smoking on the Risk of Hepatocellular Carcinoma 118
[Oxidative stress in metabolic syndrome and nonalcoholic steatohepatitis. Is it possible a role for vitamins in clinical practice?] 115
gc) Celiac disease in the 21st century: issues of under- and over-diagnosis 114
[Helicobacter pylori infection: from gastric to systemic disease] 112
Assessment of neurological manifestations in hospitalized patients with COVID-19 112
13C-breath tests in the study of mitochondrial liver function 110
Potential use of liver function breath tests in the clinical practice. 110
Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival 107
[The treatment of hepatocellular carcinoma: an update] 104
Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels 101
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 101
gastroesophageal reflux disease: facts and uncertaines 99
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome 99
Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). 98
Tromboembolism and breast cancer: the hidden risk for patient and physician 98
-Fatty liver and drugs 97
Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. 97
Cystic lymphangioma of the mesentery and hyposplenism in celiac disease. 96
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis 95
Cryoglobulinemia: a true internistic disease? 94
Intrafamilial transmission of hepatitis C virus in Italy: a systematic review 94
A case-control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease 94
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome 92
An Attempt of Specific Desensitizing Treatment with Gliadin in Coleliac Disease 91
Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression 89
A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease 88
Liver transplantation in patients with alcoholic liver disease: A retrospective study 87
Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease 86
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome 85
Gallstone disease is associated with more severe liver damage in patients with non-alcoholic Fatty liver disease 83
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease 83
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. 82
High Prevalence and Gender-Related Differences of Gastrointestinal Manifestations in a Cohort of DM1 Patients: A Perspective, Cross-Sectional Study 82
Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets 82
-Nonalcoholic fatty liver disease: defining a common problem 81
Alcoholic and nonalcoholic forms of fatty liver disease. 80
Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial 78
Braised liver with herbs: the risks of naturopathic hepatoprotection. 78
Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target 78
A case of variant angina in a patient under chronic treatment with sorafenib 76
Gender affects 13C-ketoisocaproic acid breath test 75
A giant calcified hepatic mass 75
Is coeliac disease a confounding factor in the diagnosis of NASH? 73
Review article: breath testing for human liver function assessment. 73
Socio-demographic determinants of coinfections by HIV, hepatitis B and hepatitis C viruses in central Italian prisoners. 72
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 72
Impact of new DAA therapy on real clinical practice: A multicenter region-wide cohort study 71
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 70
Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1) 69
Impairment of recent thymic emigrants in HCV infection. 68
A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease 68
The diagnostic performance of PIVKA-II in metabolic and viral hepatocellular carcinoma: A pilot study 68
Drug-induced hepatitis 67
Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH) 67
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 67
Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind 66
Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma 66
Focus on fatty liver in clinical practice 63
"tear-drop shaped" HCC 63
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 63
Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients 63
NON ALCOHOLIC STEATOHEPATITIS (NASH) INDUCED BY CARBAMAZEPINE AND VARIEGATE PORPHYRIA 62
A case of esomeprazole-induced transient diabetes and hepatitis: the role of liver inflammation in the pathogenesis of insulin resistance 62
Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome 62
anticholinergic syndrome due to " Devil's herb': when risks come from the ancient time 62
Sporadic HEV hepatitis in Italy. 61
Biology, epidemiology, clinical aspects of hepatocellular carcinoma and the role of Sorafenib 61
NAFLD and NASH: behind the fat, there's something more. 61
Propafenone-related cholestatic hepatitis in an elderly patient. 61
Mediterranean diet and the prevention of non-alcoholic fatty liver disease: Results from a case-control study 61
Enhanced liver fibrosis test as a reliable tool for assessing fibrosis in nonalcoholic fatty liver disease in a clinical setting 60
Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk 59
IgG cryoglobulinemia 58
Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk 57
COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel 57
Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 57
-The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis. 56
High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection 56
When was celiac disease born?: the Italian case from the archeologic site of Cosa 56
Acute HEV hepatitis: clinical and laboratory diagnosis 56
Totale 9.659
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.819
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.819
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.490 309 100 81 60 92 123 167 70 96 140 130 122
2020/20211.148 60 113 54 120 149 52 127 19 148 66 214 26
2021/20221.545 46 109 48 178 110 35 24 233 56 96 290 320
2022/20234.157 431 415 235 446 420 566 284 330 443 271 236 80
2023/20243.084 239 795 108 177 159 338 224 105 45 215 262 417
2024/2025129 129 0 0 0 0 0 0 0 0 0 0 0
Totale 14.661